Drugs.com New Drug ApprovalsOriginal article
Glenmark Receives U.S. FDA Approval to Expand the Use of Ryaltris Nasal Spray for Children Aged 6 to Less Than 12 Years
RegulatoryapprovedRyaltrisPositive
AI Analysis
Summary
Glenmark received FDA approval to expand Ryaltris (olopatadine hydrochloride/mometasone furoate) nasal spray use to children aged 6 to less than 12 years, representing a label expansion for the allergy/inflammatory nasal indication.
Outcome Details
FDA approved expanded use of Ryaltris Nasal Spray for pediatric patients aged 6 to less than 12 years
Importance:7/10
Sentiment:
0.85
FDA approvallabel expansionpediatric indicationRyaltrisGlenmark
Read the original article
Published by Drugs.com New Drug Approvals on July 21, 2026 7:07 PM